Thoma Bravo explores sale of identity software firm Imprivata, sources say
Summary
Thoma Bravo is exploring a sale of Imprivata and has engaged JPMorgan and Evercore to run an early-stage process. The potential transaction could value Imprivata at up to $7 billion and is expected to draw interest from corporate buyers and private equity firms. Imprivata builds identity and access management software for healthcare, generates roughly $500 million in revenue, and expanded after Thoma Bravo's 2016 take-private through add-on deals including Verosint. The possible sale would represent a substantial return on Thoma Bravo's original investment and underscores strong M&A appetite for security software as AI increases data-protection concerns.
Classifications
industries
HealthTech
applications
Human Resources
AskAI Classifications
Labels
Identity and Access Management
Cybersecurity Software
Healthcare Software
